HF50 for HER-2 positive and low-expression advanced tumors
Part of Cancer clinical trials.
This trial tests a new drug, HF50, in people with advanced solid tumors that are HER-2 positive or have low HER-2 levels. It may be an option if standard treatments have stopped working or are not tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must be confirmed as HER-2 positive or low HER-2 and has spread or come back after standard treatments.
- You must be able to do daily activities with little or no help (ECOG 0 or 1).
- You need to have at least one tumor that can be measured on scans.
- Your blood counts and organ function (heart, liver, kidneys) must be within acceptable ranges.
- You must not be pregnant and must use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new drug called HF50 in people with advanced cancers that have spread or cannot be surgically removed. The goal is to see if HF50 is safe and whether it helps shrink tumors in patients whose cancer has not responded to standard treatments.
This trial tests a new drug called HRS-4508 for people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe, how the body processes it, and if it helps shrink tumors.
This study tests an investigational drug (KM501) for advanced solid tumors that have HER2 changes. It aims to see if the drug can shrink tumors or slow their growth, and whether it is safe for patients who have run out of standard options.
This Phase 1 trial tests HF158K1 in people with advanced solid tumors that have HER2 protein. It aims to see if the drug can be given safely and learn how it works in people whose cancer shows HER2 on tumor testing.
This trial tests an investigational drug for people with advanced or metastatic HER2-positive solid tumors. The drug is designed to target cancer cells with HER2 and may slow tumor growth.
This trial tests a new drug called BM230 for people with advanced solid tumors that have HER2 protein or gene changes. It aims to see if the drug is safe and effective for those who have run out of standard treatment options.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.